WO2002002744A3 - Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof - Google Patents

Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof Download PDF

Info

Publication number
WO2002002744A3
WO2002002744A3 PCT/US2001/021350 US0121350W WO0202744A3 WO 2002002744 A3 WO2002002744 A3 WO 2002002744A3 US 0121350 W US0121350 W US 0121350W WO 0202744 A3 WO0202744 A3 WO 0202744A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
human mch1
nucleic acid
mch1
mch1 receptor
Prior art date
Application number
PCT/US2001/021350
Other languages
French (fr)
Other versions
WO2002002744A2 (en
Inventor
John A Salon
Thomas M Laz
Raisa Nagorny
Amy E Wilson
Carlos Forray
Thomas P Blackburn
Beth Borowsky
Kristine Ogazalek
Original Assignee
Synaptic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US61063500A priority Critical
Priority to US09/610,635 priority
Application filed by Synaptic Pharma Corp filed Critical Synaptic Pharma Corp
Publication of WO2002002744A2 publication Critical patent/WO2002002744A2/en
Publication of WO2002002744A3 publication Critical patent/WO2002002744A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones

Abstract

This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequence of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors. This invention provides a method of modifying the feeding behavior of a subject which comprises administering to the subject an amount of an MCH1 antagonist effective to decrease the body mass of the subject and/or decrease the consumption of food by the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of an MCH1 antagonist effective to treat the subject's depression and/or anxiety.
PCT/US2001/021350 2000-07-05 2001-07-05 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof WO2002002744A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US61063500A true 2000-07-05 2000-07-05
US09/610,635 2000-07-05

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002507986A JP2004502423A (en) 2000-07-05 2001-07-05 DNA encoding human melanin-concentrating hormone receptor (MCH1) and use thereof
EP20010952456 EP1246847A2 (en) 2000-07-05 2001-07-05 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
CA 2384358 CA2384358A1 (en) 2000-07-05 2001-07-05 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
AU73207/01A AU7320701A (en) 2000-07-05 2001-07-05 DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof

Publications (2)

Publication Number Publication Date
WO2002002744A2 WO2002002744A2 (en) 2002-01-10
WO2002002744A3 true WO2002002744A3 (en) 2002-08-08

Family

ID=24445829

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021350 WO2002002744A2 (en) 2000-07-05 2001-07-05 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof

Country Status (5)

Country Link
EP (1) EP1246847A2 (en)
JP (1) JP2004502423A (en)
AU (1) AU7320701A (en)
CA (1) CA2384358A1 (en)
WO (1) WO2002002744A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221613B1 (en) 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
AU7929401A (en) 2000-07-06 2002-01-21 Neurogen Corp Melanin concentrating hormone receptor ligands
US7078187B2 (en) 2001-04-19 2006-07-18 Neurogen Corporation Melanin concentrating hormone receptors
US7078484B2 (en) 2001-04-19 2006-07-18 Neurogen Corporation Melanin concentrating hormone receptors
US6858619B2 (en) 2001-05-04 2005-02-22 Amgen Inc. Fused heterocyclic compounds
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
WO2002094799A2 (en) 2001-05-22 2002-11-28 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
US7105544B2 (en) 2001-07-05 2006-09-12 Synaptic Pharmaceutical Corporation Substituted alkyl amido piperidines
MXPA03011886A (en) * 2001-07-05 2005-03-07 Lundbeck & Co As H Composite dosage forms having an inlaid portion.
US7199135B2 (en) 2001-07-05 2007-04-03 H. Lundbeck A/S Substituted alkyl amido piperidines
US6727264B1 (en) 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
EP1465635A4 (en) 2002-01-10 2005-04-13 Neurogen Corp Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues
WO2003059289A2 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
DE60325973D1 (en) 2002-07-03 2009-03-12 Lundbeck As Valby H Spirocyclic piperidines as mch1 antagonists and their uses
NZ536329A (en) * 2002-07-03 2007-06-29 Lundbeck & Co As H Secondary amino anilinic piperidines as MCH1 antagonists and uses thereof
DE60329513D1 (en) 2002-07-30 2009-11-12 Banyu Pharma Co Ltd Antagonist of melanine concentrating hormone receptor, containing a benzimidazole derivative as an active substance
WO2004023870A1 (en) * 2002-09-10 2004-03-25 Takeda Pharmaceutical Company Limited Human slt transgenic animal
CA2505372A1 (en) 2002-11-06 2004-05-27 Tularik Inc. Fused heterocyclic compounds
JPWO2004069798A1 (en) 2003-02-10 2006-05-25 萬有製薬株式会社 Melanin-concentrating hormone receptor antagonist containing piperidine derivative as active ingredient
AU2004241213B2 (en) 2003-05-21 2009-04-23 Banyu Pharmaceutical Co., Ltd. 2-aminoquinoline derivative
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
US7732456B2 (en) 2004-03-05 2010-06-08 Banyu Pharmaceutical Co., Ltd. Pyridone derivative
DE102004039789A1 (en) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Aryl-substituted polycyclic amines, process for their preparation and their use as pharmaceuticals
AU2006277253A1 (en) 2005-08-10 2007-02-15 Msd K.K. Pyridone compound
EP1921065B1 (en) 2005-08-24 2010-10-20 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd Bicyclic aromatic substituted pyridone derivative
KR20080094699A (en) 2006-02-15 2008-10-23 사노피-아벤티스 Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
AR075402A1 (en) 2009-02-13 2011-03-30 Sanofi Aventis Heterocyclic Derivatives oxygenated and / or nitrogenous tetrahydronaphthalene, medicaments containing them and their use in the treatment of metabolic disorders such as obesity, among others.
AR075401A1 (en) 2009-02-13 2011-03-30 Sanofi Aventis Indanes substituted, processes for their preparation and use thereof as a medicament
MX2012001729A (en) 2009-08-26 2012-06-13 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use.
EP2683698B1 (en) 2011-03-08 2017-10-04 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683703B1 (en) 2011-03-08 2015-05-27 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683702B1 (en) 2011-03-08 2014-12-24 Sanofi New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0848060A2 (en) * 1996-12-11 1998-06-17 Smithkline Beecham Corporation Novel human 11CB splice variant
WO2001005947A1 (en) * 1999-07-14 2001-01-25 Merck & Co., Inc. Melanin-concentrating hormone receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0848060A2 (en) * 1996-12-11 1998-06-17 Smithkline Beecham Corporation Novel human 11CB splice variant
WO2001005947A1 (en) * 1999-07-14 2001-01-25 Merck & Co., Inc. Melanin-concentrating hormone receptor

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
C.R. ACAD. SCI. III, SCI. VIE., vol. 318, no. 2, 1995, pages 263 - 272 *
DATABASE GENBANK [online] 20 February 1995 (1995-02-20), AUFFRAY, C. ET AL.: "HSC1ZF101 normalized infant brain cDNA homo sapiens cDNA clone c-1zf10, mRNA sequence", XP002950954, Database accession no. (F07228) *
DATABASE GENBANK [online] accession no. EMBL Database accession no. (AF008650, P97639) *
DATABASE GENBANK [online] accession no. EMBL Database accession no. (U71092, Q99705) *
KOLAKOWSKI, L.F. ET AL.: "Characterization of a human gene related to genes encoding somatostatin receptors", FEBS LETTERS, vol. 398, no. 2-3, 19 December 1996 (1996-12-19), pages 253 - 258, XP002916551 *
LAKAYE, B. ET AL.: "Cloning of the rat brain cDNA encoding for the SLC-1 G protein-coupled receptor reveals the presence of an intron in the gene", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1401, no. 2, 1998, pages 216 - 220, XP000856696 *

Also Published As

Publication number Publication date
JP2004502423A (en) 2004-01-29
CA2384358A1 (en) 2002-01-10
WO2002002744A2 (en) 2002-01-10
AU7320701A (en) 2002-01-14
EP1246847A2 (en) 2002-10-09

Similar Documents

Publication Publication Date Title
Prasad et al. Molecular cloning of the human placental folate transporter
Maruyama et al. A novel brain-specific mRNA encoding nuclear protein (necdin) expressed in neurally differentiated embryonal carcinoma cells
Filigheddu et al. Ghrelin and des-acyl ghrelin promote differentiation and fusion of C2C12 skeletal muscle cells
Nishiyama et al. A glycine-rich RNA-binding protein mediating cold-inducible suppression of mammalian cell growth
Calogero et al. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice
Spreyer et al. Axon‐regulated expression of a Schwann cell transcript that is homologous to a ‘growth arrest‐specific’gene.
Prasad et al. Molecular and functional characterization of the intestinal Na+-dependent multivitamin transporter
Nakabeppu et al. The basic region of Fos mediates specific DNA binding.
Baumbach et al. The growth hormone-binding protein in rat serum is an alternatively spliced form of the rat growth hormone receptor.
Liang et al. Activation of human B cells by phosphorothioate oligodeoxynucleotides.
Potter et al. Cloning and characterization of the cDNAs for human and rat corticotropin releasing factor-binding proteins
Kekuda et al. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1)
Benson et al. Identification of a homeodomain binding element in the bone sialoprotein gene promoter that is required for its osteoblast-selective expression
JP3231779B2 (en) Adjustment antisense oligonucleotides of raf gene expression
Shih et al. Definition of the carbohydrate response element of the rat S14 gene. Context of the CACGTG motif determines the specificity of carbohydrate regulation.
AU2002211539B2 (en) Nogo receptor homologs
Bell et al. Electro-mechanical response times and rate of force development in males and females.
JP3054745B2 (en) Adjustment antisense oligonucleotides of raf gene expression
Krupinski et al. Molecular diversity in the adenylylcyclase family. Evidence for eight forms of the enzyme and cloning of type VI.
JP2014221039A (en) Splice switching oligomers for tnf superfamily receptor and their use in disease treatment
KR100354610B1 (en) Antisense Inhibition of ras Gene with Chimeric and Alternating Oligonucleotides
JP2937481B2 (en) Oligonucleotides adjustment of multidrug resistance-associated protein
Kimura et al. Cadherin-11 expressed in association with mesenchymal morphogenesis in the head, somite, and limb bud of early mouse embryos
CA2493949C (en) Modified small interfering rna molecules and methods of use
EP1131333B1 (en) ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2002 507986

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2384358

Country of ref document: CA

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 73207/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001952456

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2001952456

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWW Wipo information: withdrawn in national office

Ref document number: 2001952456

Country of ref document: EP